| Stereochemistry | ABSOLUTE |
| Molecular Formula | C20H41NO2 |
| Molecular Weight | 327.545 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCCCCCCCCCC\C=C\[C@H](O)[C@@H](CO)N(C)C
InChI
InChIKey=YRXOQXUDKDCXME-QWKHPXNBSA-N
InChI=1S/C20H41NO2/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-20(23)19(18-22)21(2)3/h16-17,19-20,22-23H,4-15,18H2,1-3H3/b17-16+/t19-,20+/m1/s1
| Molecular Formula | C20H41NO2 |
| Molecular Weight | 327.545 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 1 |
| Optical Activity | UNSPECIFIED |
N,N-Dimethylsphingosine (also known as DMS) is an inhibitor of sphingosine kinase, which has been identified as an inducer of pain in a rat model of chronic pain. Recently was shown, that DMS through anti-parasitic and immunomodulatory actions, can be beneficial in the treatment of chronic phase of T. cruzi infection and was suggested that S1P-activated processes could be possible therapeutic targets for the treatment of Chagas disease cardiomyopathy.
Approval Year
PubMed
Patents
Sample Use Guides
in mice: C57BL/6 mice infected with trypomastigotes (Colombian strain) were treated during the chronic phase of infection (6 months pos-infection) with N, N-Dimethylsphingosine (DMS) (200 µg/Kg/day; 3x week; i.p.).
Route of Administration:
Intraperitoneal
In vitro experiments indicated that N, N-Dimethylsphingosine (DMS) induced a dose-dependent reduction in [3H]-thymidine incorporation and ERK-1/2 activation via a protein kinase C (PKC) independent mechanism with an IC50 value of 12 ± 6 and 15 ± 10 µM respectively. DMS also reduced Akt signalling.